CBER Reorganization Will Proceed Without Siegel; OTRR Director To Retire
Executive Summary
CBER Office of Therapeutics Review & Research Director Jay Siegel, MD, is the first high level departure from the agency since the announcement of the reorganization of the Center for Biologics Evaluation & Research
You may also be interested in...
CBER Director Zoon To Leave FDA In Mid-January To Return To NIH
FDA will be initiating a search for a new head of the reorganized Center for Biologics Evaluation & Research following the departure of Director Kathryn Zoon, PhD, in mid-January
CBER Director Zoon To Leave FDA In Mid-January To Return To NIH
FDA will be initiating a search for a new head of the reorganized Center for Biologics Evaluation & Research following the departure of Director Kathryn Zoon, PhD, in mid-January
FDA Oncology Reviews Could Remain Split After CBER/CDER Reorganization
FDA is understood to be considering the creation of two divisions within the Center for Drug Evaluation & Research to review oncologic products as part of the CBER/CDER reorganization